Apixaban to help arm fistulas mature in people with end-stage kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study gives perioperative and short-term apixaban around the time of primary upper-extremity arteriovenous fistula creation to reduce microthrombotic events during the critical 4–6 week maturation period. Eligible adults have end-stage renal disease (eGFR <15 mL/min/1.73 m2 or on dialysis) and suitable vessels on preoperative duplex ultrasound. Key exclusions include therapeutic anticoagulation, dual antiplatelet therapy, bleeding diathesis, prior intracranial hemorrhage, or apixaban hypersensitivity. The main outcomes are fistula maturation rates and safety, particularly bleeding complications, with all procedures and follow-up at the enrolling hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years.
* Diagnosis of ESRD (eGFR \< 15 mL/min/1.73m² or already on dialysis) with plans for hemodialysis.
* Planned primary upper extremity AVF creation (radiocephalic, brachiocephalic, or brachiobasilic).
* Suitable vessels on preoperative duplex ultrasound (artery ≥ 2 mm, vein ≥ 2.5 mm without tourniquet).
* Ability to provide informed consent.

Exclusion Criteria:

* Known bleeding diathesis or hypercoagulable state.
* Current therapeutic anticoagulation (any indication).
* Current dual antiplatelet therapy.
* History of intracranial hemorrhage.
* Known allergy or hypersensitivity to apixaban.
* Inability to comply with study protocol or follow-up.

Where it's running

• Combined Military Hospital, Lahore
  Lahore, Punjab Province, Pakistan Recruiting

Study contacts

• Study coordinator: Muhammad Kashif, FCPS Surgery
• Email: kashiramzan@gmail.com
• Phone: 00923219698888

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bleeding after oral soft tissue biopsy in people taking DOAC blood thinners

  This study will test whether continuing DOAC blood thinners is safe for people having an excisional oral soft tissue biopsy by comparing bleeding in 50 patients on uninterrupted DOACs with 50 patients not on anticoagulants.

  Recruiting University of Pisa · Pisa, Pi · NCT07520890

• Single-needle distal return for long-term AV fistula care

  This trial tests a single-needle method that draws blood from your arm fistula and returns it through a foot or lower-leg vein to see if it reduces damage and the need for repeat procedures in adults on thrice-weekly hemodialysis.

  Recruiting Suzhou Municipal Hospital of Anhui Province · Suzhou, Anhui · NCT07372027

• Liquid embolic treatment for brain arteriovenous malformations

  This study will test a new liquid embolic agent against the Onyx system in adults (18–80) with brain arteriovenous malformations to see if it is as safe and effective.

  Recruiting MicroPort NeuroTech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07314047

• Timing of hip fracture surgery for patients on DOAC blood thinners

  This project will see if operating within 24 hours is as safe as delaying surgery for people with hip fractures who recently took DOAC blood thinners by comparing how often they need blood transfusions.

  Recruiting at 7 sites St. Antonius Hospital · Almelo and 6 other locations · NCT07309848

• Velocity pAVF system for creating dialysis fistulas through a small skin puncture

  This trial will test whether the minimally invasive Velocity pAVF system can create a dependable dialysis fistula in adults with kidney failure or those expected to need hemodialysis soon.

  Recruiting at 13 sites Venova Medical · Dothan, Alabama and 12 other locations · NCT07153939

• Comparing drug-coated balloons to plain balloons for treating AVF stenosis

  This study is testing if a special drug-coated balloon works better than a regular balloon for treating narrow spots in blood vessels for patients with arteriovenous fistula stenosis.

  Recruiting Phase 3 Singapore General Hospital · Singapore · NCT06553443

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.